Spyre Therapeutics
SYRE
93.47
-4.16
-4.26%
Spyre Therapeutics
US · SYRE
#1646 by market cap
Listed 1970
93.47
-4.16
-4.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $116 to $130Market Newswire · 2026/8/27
-
J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $116Market Newswire · 2026/11/13
-
Rating change
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $140Market Newswire · 2026/8/13
-
Rating change
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121Market Newswire · 2026/10/20
-
Rating change
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123Market Newswire · 2026/8/14
-
Rating change
Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $119Market Newswire · 2026/10/21
-
Rating change
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129Market Newswire · 2026/8/15
-
Rating change
Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $126Market Newswire · 2026/9/9
-
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123Market Newswire · 2026/10/20
-
Rating change
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130Market Newswire · 2026/10/1
-
Rating change
Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $119Market Newswire · 2026/10/20
-
Rating change
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127Market Newswire · 2026/8/26
-
Rating change
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121Market Newswire · 2026/9/28
-
UBS Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $120Market Newswire · 2026/10/12
-
Rating change
Leerink Partners Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128Market Newswire · 2026/9/9
-
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/11/6
-
Rating change
J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $110Market Newswire · 2026/10/1
-
Rating change
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $116Market Newswire · 2026/9/9
-
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $131Market Newswire · 2026/11/5
-
Rating change
Guggenheim Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/8/27
-
Rating change
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/10/4
-
Rating change
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $129Market Newswire · 2026/8/11
-
Rating change
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130Market Newswire · 2026/8/11
-
Rating change
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $132Market Newswire · 2026/8/11
-
Rating change
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128Market Newswire · 2026/8/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Spyre Therapeutics discussion 0 comments